1-7 of 7
Tatsuro Watanabe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Shinya Kimura, Kensuke Usuki, Tatsuo Ichinohe, Takayuki Ikezoe, Junya Kuroda, Senji Kasahara, Sho Okamoto, Hiromitsu Iizuka, Hiroshi Ureshino, Tatsuro Watanabe, Tokihiro Ro, Kosuke Endo, Yuka Kagawa, Yuki Kurahashi, Toshiki Naito, Takahiro Yamauchi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6466.
https://doi.org/10.1182/blood-2023-173174
Published: 2023
Journal Articles

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abhishek Maiti, Satoshi Yamashita, Abdullah Khasawneh, Faith Jessica Paran, Kala Hayes, Gautam Borthakur, Joe R Harman, Shinya Kimura, Courtney D. DiNardo, Thomas A Milne, Michael Andreeff, Yoko Tabe, Marina Y. Konopleva
Journal: Blood
Blood (2023) 142 (Supplement 1): 4162.
https://doi.org/10.1182/blood-2023-178554
Published: 2023
Journal Articles

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva
Journal: Blood
Blood (2022) 140 (Supplement 1): 3097–3098.
https://doi.org/10.1182/blood-2022-156999
Published: 2022
Journal Articles

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka
Journal: Blood
Blood (2020) 136 (7): 871–884.
https://doi.org/10.1182/blood.2019003084
Published: 2020
Includes: Supplemental data
Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5365.
https://doi.org/10.1182/blood-2019-125460
Published: 2019
Journal Articles

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Tatsuro Watanabe, PhD, Hiroshi Ureshino, MD, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Satoshi Yamashita, PhD, Toshikazu Ushijima, MD PhD, Seiji Okada, MD PhD, Eisaburo Sueoka, MD PhD, Shinya Kimura, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4175.
https://doi.org/10.1182/blood-2018-99-117536
Published: 2018
Journal Articles

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

Hiroshi Ureshino, MD, Tatsuro Watanabe, PhD, Yuki Kurahashi, Yuki Fukuda Kurahashi, Kaoru Tohyama, MD, Seiji Okada, MD PhD, Toshikazu Ushijima, MD PhD, Hiroshi Ureshino, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5499.
https://doi.org/10.1182/blood-2018-99-112362
Published: 2018